Pedro de Cosio

Investment Manager

4 past transactions

Bioeureka

Pre Seed Round in 2024
Bioeureka is an innovative company revolutionizing microbiology with advanced AI-powered image recognition technology for rapid pathogen identification.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Irvine, California, that specializes in the development and commercialization of innovative therapeutic candidates for ophthalmic conditions. Its primary focus is on TP-03, a novel treatment currently in Phase IIb/III trials for blepharitis caused by Demodex mite infestations, as well as meibomian gland disease. The company is also advancing additional candidates, including TP-04 for rosacea and TP-05 for Lyme disease prophylaxis and community malaria reduction. Tarsus aims to address significant unmet medical needs in various therapeutic areas, initially concentrating on eye care where treatment options are limited. Founded in 2016, Tarsus Pharmaceuticals continues to expand its pipeline to include diverse diseases across different medical fields.
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for pain management and addiction medicine. Headquartered in Raleigh, North Carolina, the company utilizes its proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology, which features a small erodible polymer film designed for application to the buccal mucosa. Its product offerings include BELBUCA, a buprenorphine buccal film for chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for opioid dependence; ONSOLIS, a fentanyl buccal soluble film for breakthrough cancer pain; and Symproic, which addresses opioid-induced constipation in adult patients with chronic non-cancer pain. Founded in 1997, BioDelivery Sciences is committed to addressing significant unmet medical needs through innovative therapeutic solutions.

NovoCure

Post in 2018
NovoCure Limited is an oncology company focused on the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) therapy, specifically through its flagship product, Optune. This innovative treatment targets solid tumors, including glioblastoma, by utilizing electric fields to disrupt cancer cell division, thereby slowing or reversing tumor progression. In addition to Optune, the company is advancing a pipeline of products, including those in Phase 2 and Phase 3 clinical trials for various cancers such as brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. NovoCure markets its devices in the European Union, Japan, and other international markets, and has established collaborations to enhance its research and development efforts. Founded in 2000 and headquartered in Saint Helier, Jersey, NovoCure aims to provide effective treatment options for patients battling cancer through its innovative technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.